Pr Gregor Verhoef - CML - Chronic myeloid leukemia
Researcher of department of Hematology,
UZ Leuven Gasthuisberg Hematologie, Leuven, Belgium
UZ Leuven Gasthuisberg Hematologie, Leuven, Belgium
ARTICLES
Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: A randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON).
June 18, 2013, PubMed
High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group.
April 2013, PubMed
Aanbevelingen voor de behandeling van chronische myeloide leukemie namens de HOVON Leukemie werkgroep
January 2010, OAI
Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia
December 2009, PubMed
Reduction of BCR-ABL1 mutant clones after discontinuation of TKI therapy.
June 2009, PubMed
Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study.
December 2008, PubMed
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
December 2006, PubMed
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
March 2003, PubMed
Imatinib mesylate induces durable complete remission of advanced CML persisting after allogeneic bone marrow transplantation
March 2003, PubMed
Chronic myelogenous leukemia after treatment with 131I for thyroid carcinoma. Report of a case and review of the literature.
October 1991, PubMed
Philadelphia chromosome-positive chronic myelogenous leukemia in treated Hodgkin's disease
November 1990, PubMed
Pyoderma gangrenosum in a patient with chronic myeloid leukemia.
February 1990, PubMed
Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: A randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON).
June 18, 2013, PubMed
High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group.
April 2013, PubMed
Aanbevelingen voor de behandeling van chronische myeloide leukemie namens de HOVON Leukemie werkgroep
January 2010, OAI
Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia
December 2009, PubMed
Reduction of BCR-ABL1 mutant clones after discontinuation of TKI therapy.
June 2009, PubMed
Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study.
December 2008, PubMed
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
December 2006, PubMed
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
March 2003, PubMed
Imatinib mesylate induces durable complete remission of advanced CML persisting after allogeneic bone marrow transplantation
March 2003, PubMed
Chronic myelogenous leukemia after treatment with 131I for thyroid carcinoma. Report of a case and review of the literature.
October 1991, PubMed
Philadelphia chromosome-positive chronic myelogenous leukemia in treated Hodgkin's disease
November 1990, PubMed
Pyoderma gangrenosum in a patient with chronic myeloid leukemia.
February 1990, PubMed